Observation for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how lung cancer changes over time and how a blood test might predict the risk of cancer returning or assess treatment effectiveness. It focuses on patients with non-small cell lung cancer (NSCLC). The trial includes two groups: one with early-stage cancer considering surgery and another with advanced-stage cancer receiving immunotherapy, which helps the immune system fight cancer. Patients with NSCLC receiving these treatments may be suitable candidates, especially if they agree to extra blood tests during check-ups. One approach under study is Observation (also known as Watchful waiting or Active surveillance), which involves closely monitoring a patient's condition without treatment unless test results change. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It seems to focus on collecting health information and blood samples while you continue your standard care.
Why are researchers excited about this trial?
Researchers are excited about the GEMINI-NSCLC trial because it aims to refine and personalize treatment approaches for non-small cell lung cancer (NSCLC) by examining important biomarkers. Unlike standard treatments, which often follow a one-size-fits-all approach, this trial seeks to understand how different patients respond to surgery, perioperative therapy, or first-line immunotherapy. By observing and analyzing patient data, researchers hope to improve treatment outcomes by identifying which therapies work best for specific patient profiles. This could lead to more effective and tailored treatment strategies, potentially improving survival rates and quality of life for NSCLC patients.
Who Is on the Research Team?
Virginia Rhodes, MD
Principal Investigator
Tempus AI, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Standard of Care Therapy
Participants receive standard of care therapy, including surgery and/or immunotherapy, with longitudinal blood collection
Disease Surveillance
Participants undergo regular monitoring to assess disease progression and molecular changes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Observation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tempus AI
Lead Sponsor
Tempus Labs
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology